Among patients not undergoing curative-intent therapy for esophagogastric cancer, access to care may vary. We examined the geographic distribution of care delivery and survival and their relationship with distance to cancer centres for non-curative esophagogastric cancer, hypothesising that patients living further from cancer centres have worse outcomes.
We conducted a population-based analysis of adults with non-curative esophagogastric cancer from 2005 to 2017 using linked administrative healthcare datasets in Ontario, Canada. Outcomes were medical oncology consultation, receipt of chemotherapy, and overall survival. Using geographic information system analysis, we mapped locations of cancer centres and outcomes across census divisions. Bivariate choropleth maps identified regional outcome discordances. Multivariable regression models assessed the relationship between distance from patient residence to the nearest cancer centre and outcomes, adjusting for demographic, clinical, and socioeconomic factors.
Of 10,228 patients surviving a median 5.1 months (IQR: 2.0–12.0), 68.5% had medical oncology consultation and 32.2% received chemotherapy. Certain distances (reference ≤ 10 km) were associated with lower consultation [relative risk 0.79 (95% CI 0.63–0.97) for ≥ 101 km], chemotherapy receipt [relative risk 0.67 (95% CI 0.53–0.85) for ≥ 101 km], and overall survival [hazard ratio 1.07 (95% CI 1.02–1.13) for 11–50 km, hazard ratio 1.13 (95% CI 1.04–1.23) for 51–100 km].
A third of patients did not see medical oncology and most did not receive chemotherapy. Outcomes exhibited high geographic variability. Location of residence influenced outcomes, with inferior outcomes at certain distances > 10 km from cancer centres. These findings are important for designing interventions to reduce access disparities for non-curative esophagogastric cancer care.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Fitzmaurice C, Akinyemiju TF, Lami FHA, Alam T, Alizadeh-Navaei R, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4:1553–68.
Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19:5598–606.
Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D’Amico TA, Das P, et al. Clinical practice guidelines in oncologyTM. J Natl Compr Canc Netw. 2010;8:32.
Hallet J, Davis LE, Mahar AL, Liu Y, Zuk V, Gupta V, et al. Variation in receipt of therapy and survival with provider volume for medical oncology in non-curative esophago-gastric cancer: a population-based analysis. Gastric Cancer. 2020;23:300–9.
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24:4991–7.
Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
MacKenzie M, Spithoff K, Jonker D. Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr Oncol. 2011;18:e202–9.
Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015;13:194–227.
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38-49.
Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS. SSO and TOS Ann Oncol. 2019;30:19–33.
Sinding C, Warren R, Fitzpatrick-Lewis D, Sussman J. Research in cancer care disparities in countries with universal healthcare: mapping the field and its conceptual contours. Support Care Cancer. 2014;22:3101–20.
O’Connor SC, Mogal H, Russell G, Ethun C, Fields RC, Jin L, et al. The effects of travel burden on outcomes after resection of extrahepatic biliary malignancies: results from the US extrahepatic biliary consortium. J Gastrointest Surg. 2017;21:2016–24.
Lin CC, Bruinooge SS, Kirkwood MK, Olsen C, Jemal A, Bajorin D, et al. Association between geographic access to cancer care, insurance, and receipt of chemotherapy: geographic distribution of oncologists and travel distance. J Clin Oncol. 2015;33:3177–85.
Latchana N, Davis L, Coburn NG, Mahar A, Liu Y, Hammad A, et al. Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarcinoma: effect of location of surgical and adjuvant therapy on survival in pancreatic adenocarcinoma. BJS Open. 2019;3:85–94.
Kim Y-E, Gatrell AC, Francis BJ. The geography of survival after surgery for colo-rectal cancer in southern England. Soc Sci Med. 2000;50:1099–107.
Dejardin O, Bouvier AM, Faivre J, Boutreux S, De Pouvourville G, Launoy G. Access to care, socioeconomic deprivation and colon cancer survival. Aliment Pharmacol Ther. 2008;27:940–9.
Tracey E, McCaughan B, Badgery-Parker T, Young J, Armstrong BK. Patients with localized non-small cell lung cancer miss out on curative surgery with distance from specialist care: access to curative surgery in NSCLC patients. ANZ J Surg. 2015;85:658–63.
Dixon M, Mahar AL, Helyer LK, Vasilevska-Ristovska J, Law C, Coburn NG. Prognostic factors in metastatic gastric cancer: results of a population-based, retrospective cohort study in Ontario. Gastric Cancer. 2016;19:150–9.
Mahar AL, Coburn NG, Kagedan DJ, Viola R, Johnson AP. Regional variation in the management of metastatic gastric cancer in Ontario. Curr Oncol. 2016;23:250–7.
Davis LE, Coburn NG, Hallet J, Earle CC, Liu Y, Myrehaug S, et al. (2020) Material deprivation and access to cancer care in a universal health care system. Cancer. cncr.33107.
Yee EK, Coburn NG, Davis LE, Mahar AL, Zuk V, Gupta V, et al. Impact of geography on care delivery and survival for noncurable pancreatic adenocarcinoma: a population-based analysis. J Natl Compr Canc Netw. 2020;18:1642–50.
Canada health act. 2004 [cited 2019 Aug 21]. Available from: https://www.canada.ca/en/health-canada/services/health-care-system/canada-health-care-system-medicare/canada-health-act.html
Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLOS Med. 2015;12:e1001885.
Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med. 1999;341:1359–67.
Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.
Gutacker N, Bloor K, Cookson R. Comparing the performance of the Charlson/Deyo and Elixhauser comorbidity measures across five European countries and three conditions. Eur J Public Health. 2015;25:15–20.
Matheson FI, Dunn JR, Smith KL, Moineddin R, Glazier RH. Development of the Canadian marginalization index: a new tool for the study of inequality. Can J Public Health. 2012;103:S12-16.
Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82:703–10.
Iron K, Zagorski BM, Sykora K, Manuel DG. Living and dying in ontario: an opportunity for improved health information. Toronto: Institute for clinical evaluative sciences; 2008. p. 38.
Robles SC, Marrett LD, Aileen Clarke E, Risch HA. An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol. 1988;41:495–501.
Juurlink D, Preyra C, Croxford R, Chong A, Austin P, Tu J, et al. Canadian Institute for Health Information Discharge Abstract Database: a Validation Study. Toronto: Institute for Clinical Evaluative Sciences; 2006.
Government of Canada SC. Postal code OM conversion file. 2017 [cited 2019 Aug 21]. Available from: https://www150.statcan.gc.ca/n1/en/catalogue/92-154-X.
Government of Canada SC. Census divisions [Internet]. [cited 2019 Aug 21]. Available from: https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/hlt-fst/imm/GeoSelect-eng.cfm?Lang=E&T=23.
Government of Canada SC. 2016 Census boundary files. 2016 [cited 2019 Aug 21]. Available from: https://www12.statcan.gc.ca/census-recensement/2011/geo/bound-limit/bound-limit-2016-eng.cfm
2014–2019 Systemic treatment provincial plan. Cancer care Ontario; 2014.
Meilleur A, Subramanian SV, Plascak JJ, Fisher JL, Paskett ED, Lamont EB. Rural residence and cancer outcomes in the united states: issues and challenges. Cancer Epidemiol Biomarkers Prev. 2013;22:1657–67.
Paszat LF, Mackillop WJ, Groome PA, Zhang-Salomons J, Schulze K, Holowaty E (1998). Radiotherapy for breast cancer in Ontario: rate variation associated with region, age and income. Clin Invest Med 21.
Johnston GM, Boyd CJ, Joseph P, MacIntyre M. Variation in delivery of palliative radiotherapy to persons dying of cancer in nova scotia, 1994 to 1998. J Clin Oncol. 2001;19:3323–32.
Townsley C, Pond GR, Peloza B, Kok J, Naidoo K, Dale D, et al. Analysis of treatment practices for elderly cancer patients in Ontario. Canada J Clin Oncol. 2005;23:3802–10.
Groome PA, Schulze KM, Keller S, Mackillop WJ. Demographic Differences between Cancer Survivors and those who Die Quickly of their Disease. Clin Oncol. 2008;20:647–56.
Alvino DML, Chang DC, Adler JT, Noorbakhsh A, Jin G, Mullen JT. How far are patients willing to travel for gastrectomy? Ann Surg. 2017;265:1172–7.
Fong ZV, Loehrer AP, Fernández-del Castillo C, Bababekov YJ, Jin G, Ferrone CR, et al. Potential impact of a volume pledge on spatial access: a population-level analysis of patients undergoing pancreatectomy. Surgery. 2017;162:203–10.
Mavros MN, Coburn NG, Davis LE, Mahar AL, Liu Y, Beyfuss K, et al. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. Can Med Assoc J. 2019;191:E574–80.
Matheson FI, Moloney G, van Ingen T (2016) Ontario marginalization index user guide. Providence St. Joseph’s and St. Michael’s Healthcare
Maddison AR, Asada Y, Urquhart R. Inequity in access to cancer care: a review of the Canadian literature. Cancer Causes Control. 2011;22:359–66.
Groux Ph, Anchisi S, Szucs Th. Are cancer patients willing to travel more or further away for a slightly more efficient therapy? Cancer Clin Oncol. 2014;3:36–42.
Resio BJ, Chiu AS, Hoag JR, Brown LB, White M, Omar A, et al. Motivators, barriers, and facilitators to traveling to the safest hospitals in the united states for complex cancer surgery. JAMA Netw Open. 2018;1:e184595.
Symer MM, Abelson JS, Yeo HL. Barriers to regionalized surgical care: public perspective survey and geospatial analysis. Ann Surg. 2019;269:73–8.
Brewer CA. Basic mapping principles for visualizing cancer data using geographic information systems (GIS). Am J Prev Med. 2006;30:S25-36.
Sears J, Khan K, Ardern CI, Tamim H. Potential for patient-physician language discordance in Ontario. BMC Health Serv Res. 2013;13:535.
Walter SD. The analysis of regional patterns in health data: II. The power to detect environmental effects. Am J Epidemiol. 1992;136:742–59.
Dumbrava MI, Burmeister EA, Wyld D, Goldstein D, O’Connell DL, Beesley VL, et al. Chemotherapy in patients with unresected pancreatic cancer in Australia: a population-based study of uptake and survival. Asia Pac J Clin Oncol. 2018;14:326–36.
Evans DB, Hsu J, Boerma T. Universal health coverage and universal access. Bull World Health Organ. 2013;91:546-546A.
Levit LA, Byatt L, Lyss AP, Paskett ED, Levit K, Kirkwood K, et al. Closing the rural cancer care gap: three institutional approaches. JCO Oncol Pract. 2020;16:422–30.
Burge FI, Lawson BJ, Johnston GM, Grunfeld E. A population-based study of age inequalities in access to palliative care among cancer patients. Med Care. 2008;46:1203–11.
Turner M, Fielding S, Ong Y, Dibben C, Feng Z, Brewster DH, et al. A cancer geography paradox? Poorer cancer outcomes with longer travelling times to healthcare facilities despite prompter diagnosis and treatment: a data-linkage study. Br J Cancer. 2017;117:439–49.
Massarweh NN, Chiang Y-J, Xing Y, Chang GJ, Haynes AB, You YN, et al. Association between travel distance and metastatic disease at diagnosis among patients with colon cancer. J Clin Oncol. 2014;32:942–8.
Ahmed S, Shahid RK. Disparity in cancer care: a Canadian perspective. Curr Oncol. 2012 [cited 2019 Aug 21];19. Available from: http://www.current-oncology.com/index.php/oncology/article/view/1177.
Baldwin L-M, Cai Y, Larson EH, Dobie SA, Wright GE, Goodman DC, et al. Access to cancer services for rural colorectal cancer patients. J Rural Health. 2008;24:390–9.
O’Gorman LD, Hogenbirk JC, Warry W. clinical telemedicine utilization in Ontario over the Ontario telemedicine network. Telemed E-Health. 2016;22:473–9.
Brown EM. The Ontario telemedicine network: a case report. Telemed E-Health. 2013;19:373–6.
Birkmeyer JD, Goodney PP, Lucas FL (2003) Surgeon volume and operative mortality in the United States. N Engl J Med 11.
Bilimoria KY, Bentrem DJ, Feinglass JM, Stewart AK, Winchester DP, Talamonti MS, et al. Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. J Clin Oncol. 2008;26:4626–33.
Gooiker GA, van Gijn W, Wouters MWJM, Post PN, van de Velde CJH, Tollenaar RAEM, et al. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg. 2011;98:485–94.
Hallet J, Davis L, Mahar A, Mavros M, Beyfuss K, Liu Y, et al. Benefits of high-volume medical oncology care for noncurable pancreatic adenocarcinoma: a population-based analysis. J Natl Compr Canc Netw. 2020;18:297–303.
Hallet J, Look Hong NJ, Zuk V, Davis LE, Gupta V, Earle CC, et al. (2019) Economic impacts of care by high-volume providers for non-curative esophagogastric cancer: a population-based analysis. Gastric Cancer. [cited 2020 Mar 27]; Available from: http://link.springer.com/https://doi.org/10.1007/s10120-019-01031-w.
Birkmeyer JD. Regionalization of high-risk surgery and implications for patient travel times. JAMA. 2003;290:2703–8.
Stitzenberg KB, Sigurdson ER, Egleston BL, Starkey RB, Meropol NJ. Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol. 2009;27:4671–8.
Diaz A, Pawlik TM. Optimal location for centralization of hospitals performing pancreas resection in California. JAMA Surg. 2020;155:261–3.
Openshaw S. The modifiable areal unit problem. Norwich: Geo books; 1983.
This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed herein are those of the authors, and not necessarily those of CIHI. Parts of this material are based on data and information provided by Cancer Care Ontario (CCO). The opinions, results, view, and conclusions reported in this paper are those of the authors and do not necessarily reflect those of CCO. No endorsement by CCO is intended or should be inferred.
This work was supported by the Canadian Institutes of Health Research Partnerships for Health System Improvement (Grant number 154131).
Conflict of interest
Julie Hallet has received speaking honoraria from Ipsen Biopharmaceuticals Canada and Novartis Oncology. Natalie G. Coburn receives salary support from Cancer Care Ontario as the Clinical Lead for Patient Reported Outcomes.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. For the conduct of this retrospective population-based study, informed consent was waived by the Research Ethics Board of Sunnybrook Health Sciences Centre.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
About this article
Cite this article
Yee, E.K., Coburn, N.G., Zuk, V. et al. Geographic impact on access to care and survival for non-curative esophagogastric cancer: a population-based study. Gastric Cancer (2021). https://doi.org/10.1007/s10120-021-01157-w